WE ARE COMMITTED TO THE CONTINUED DEVELOPMENT AND COMMERCIALIZATION OF NOVEL THERAPIES ADDRESSING UNMET MEDICAL NEEDS.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros™ is a product candidate in the United States for the treatment of erectile dysfunction, which Apricus in-licensed from Warner Chilcott Inc., now a subsidiary of Allergan. RayVa™ is our product candidate in Phase 2 development for the treatment of circulatory disorder Raynaud’s Phenomenon, secondary to scleroderma, which Apricus owns worldwide.